Media coverage about Immune Design (NASDAQ:IMDZ) has been trending somewhat positive recently, Accern reports. Accern identifies negative and positive news coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Immune Design earned a coverage optimism score of 0.11 on Accern’s scale. Accern also gave news headlines about the biotechnology company an impact score of 47.547622049757 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
Shares of Immune Design (NASDAQ IMDZ) traded up $0.05 during trading on Wednesday, reaching $3.75. The company’s stock had a trading volume of 745,300 shares, compared to its average volume of 315,390. Immune Design has a 12-month low of $3.55 and a 12-month high of $13.05.
Immune Design (NASDAQ:IMDZ) last announced its earnings results on Wednesday, November 1st. The biotechnology company reported ($0.52) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.63) by $0.11. The company had revenue of $0.52 million for the quarter, compared to analysts’ expectations of $0.62 million. Immune Design had a negative return on equity of 68.69% and a negative net margin of 619.62%. equities research analysts expect that Immune Design will post -1.89 EPS for the current fiscal year.
In other Immune Design news, major shareholder Leo Guthart purchased 10,000 shares of the company’s stock in a transaction that occurred on Monday, September 18th. The shares were acquired at an average cost of $9.70 per share, for a total transaction of $97,000.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Franklin M. Berger purchased 25,000 shares of the company’s stock in a transaction that occurred on Wednesday, October 25th. The shares were acquired at an average price of $4.26 per share, for a total transaction of $106,500.00. Following the completion of the acquisition, the director now directly owns 50,000 shares of the company’s stock, valued at approximately $213,000. The disclosure for this purchase can be found here. Insiders have purchased 5,300,000 shares of company stock worth $21,874,900 over the last quarter. 20.70% of the stock is currently owned by corporate insiders.
TRADEMARK VIOLATION WARNING: “Somewhat Positive Press Coverage Somewhat Unlikely to Affect Immune Design (NASDAQ:IMDZ) Stock Price” was posted by StockNewsTimes and is the property of of StockNewsTimes. If you are reading this story on another domain, it was illegally stolen and republished in violation of US & international copyright & trademark laws. The legal version of this story can be read at https://stocknewstimes.com/2017/12/13/immune-design-imdz-earning-somewhat-favorable-press-coverage-study-shows.html.
About Immune Design
Immune Design Corp. is a clinical-stage immunotherapy company. The Company is focused on cancer with in vivo approaches designed to enable the body’s immune system to fight disease. The Company has engineered its technologies to activate the immune system’s natural ability to create tumor-specific cytotoxic T cells (CTLs) to fight cancer.
Receive News & Ratings for Immune Design Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immune Design and related companies with MarketBeat.com's FREE daily email newsletter.